### **Dedication**

I dedicate this work to,

My family in thanks for all of their loving support.....and encouraging me to challenge myself....

#### Acknowledgement

I would like to express my gratitude to Dr.Bassam for being an outstanding advisor and excellent supervisor. His constant encouragement, support, and invaluable suggestions made this work successful.

I would like to give acknowledgement to the family of College of Business Studies for their constant support and help.

My sincere thanks go to Prof .Maowia Mohamed Mukhtar — Institute of Endemic Diseases — University of Khartoum for providing me with the research materials. I want also to acknowledge the family of the Institute especially Dr.Elwaleed M.Elamin for his useful advises and continues support, and Ahmed Daffallah for his kind help and collaboration.

I also would like to thank all my colleagues and friends for their endless support, hope and encouragement.

I am deeply and forever indebted to my parents for their love, support and encouragement throughout my entire life. I am also very grateful to my sisters Sahar ,Sulafa and Rayan ,and to my only brother Mohamed for their tireless efforts during my study.

## **Abstract**

This study analyzed data collected during the periods from (January 2006) to (November 2006) Rashid village in Gadarif state. These data represented information about the immunity of Leishmaniasis disease.

Three surveys were carried out by the group of researchers from the Institute of Endemic diseases. The main study sample was children of the ages between (6-19) years.

This study examined the different factors immunity impregnability associated with the disease influence, epidemiology and prevalence.

The objective of this study is to use the logistic regression model to determine the immunity factors which is more effectively in disease.

This research depends on the Statistical Package for Social Sciences (SPSS) in the analysis and getting the result of the data.

The results showed that in this study the female proportion was higher than the male. And the result showed that the Massalet has higher percentage than the other Tribes. Also we could observe that there was a high negative proportion in the tests Leishmanin Skin Test (LST (and Direct Agglutination Test (DAT) and Polymerases Chain Reaction (PCR).

From our results and from a statistical view we recommend using Leishmanin Skin Test (LST) and Direct Agglutination Test (DAT) as a good diagnostic tests for Leishmaniasis in Sudan.

### 

#### **List of Abbreviations**

AIDS : Acquired Immunodeficiency Syndrome

BCG : Bacillus Calmette-Guérin

**CL** : Cutaneous Leishmaniasis

**ELISA:** Enzyme-Linked Immunosorbent Assay

HIV : Human Immunodeficiency Virus

**IFAT** : Indirect Immunofluorescent Antibody Test

IL : Interleukin Leishmaniasis

**KDNA**: Kinetoplast DNA

MCL : Muco-Cutaneous Leishmaniasis

**ML** : Maximum Likelihood

MP : Maximum Parsimony

PCR : Polymerases Chain Reaction

**LST**: Leishmanin Skin Test

**VL** : Visceral Leishmaniasis

**DAT** : Direct Agglutination test

**PKDL**: Post Kala-azar Dermal Leishmaniasis

**ABCD**: Amphotericin B Cholesterol Dispersion

**ABLC**: Ampho-tericin B Lipid Complex

**P\_Infec**: Leishmania Past-Infection

## **List of Contents**

No.	Title	Page
1	Dedication	I
2	Acknowledgment	II
3	Abstract	III
4	Abstract in Arabic	IV
5	List of Abbreviation	V
6	List of Contents	VI
7	List of Tables	IX
8	List of Figure	X
Chapter 1	:Introduction:	
9	1.1 General Introduction	1
10	1.2 Research Problem	1
11	1.3 Research Significance	1
12	1.4 Research Goals	2
13	1.5 Research Hypotheses	2
14	1.6 Research Methodology	2
15	1.6.1 Work plan	2
16	1.6.2 Study design	3
17	1.6.3 Study Site	3
18	1.6.4 Consent form	3
19	1.6.5 Surveys	3
20	1.6.6 Samples	4
21	1.7 Data	6
22	1-8 Research Organization	6
Chapter 2	: Leishmaniasis	
23	2.1 Introduction	8
24	Title	Page
25	2.2 Leishmania Vectors	8
26	2.3 Animal Reservoirs	9
27	1.4 Clinical Forms of Leishmaniasis	9
29	2.4.1 Cutaneous Leishmaniasis (CL)	9
30	2.4.2 Muco-Cutaneous Leishmaniasis (MCL)	10
32	2.4.3 Visceral Leishmaniasis (Kala-azar)	10
32	2.4.4 Post-Kala-Azar Dermal Leishmaniasis (PKDL)	11
33	2.5 Leishmania /HIV co infection	11
34	2.6 Leishmaniasis in Sudan	12
35	2.7 Diagnosis of Leishmaniasis	13
36	2.8 Treatment of Leishmaniasis	14
37	2.9 Control of Leishmaniasis	15

Chapter 3	: logistic regression	
38	The model of the Logistic Regression Model 3-1	17
39	Wald Test 3-2	18
40	Likelihood-Ratio Test 3-3	18
41	Hosmer-Lemshow Goodness of Fit Test 3-4	19
Chapter 4	: Analysis and Discussion	
42	4-1 : Description of Study Variables	20
43	1- Age.	20
44	2- Gender.	22
45	3- Tribe.	23
46	4 - Leishmania Past-Infection .	24
47	5 - Leishmanin Skin Test (Lst1)	25
48	6- Direct Agglutination Test (Dat1)	26
49	7- Polymerases Chain Reaction (Pcr1)	27
50	8- leishmanin skin test (Lst2).	28
No.	Title	Page
51	9- Direct Agglutination Test (Dat2) .	29
52	10 - Polymerases Chain Reaction (Pcr2)	30
53	11- Leishmanin Skin Test (Lst3) .	31
54	12 - Direct Agglutination Test (Dat3) .	32
55	13 - Polymerases Chain Reaction (Pcr3).	33
56	4-2 Relations Among Study Variables	35
57	4-3 The Logistic Model Results	38
58	4-3-1 The Model's Variables	38
59	4-3-2 The Model's Results	38
60	4.4.3 The goodness of conciliation the logistic regression model	39
61	4.4.4 The determining factor for the logistic regression model	40
Chapter 5	: Results and Recommendations	
62	5-1 Results	42
63	5-2 Recommendations	43
64	References	44

## **List of Table**

No.	Title	Page
4-1	The frequency distribution of respondents according to age	20
4-2	The frequency distribution of respondents according to gender	22
4-3	The frequency distribution of respondents according to tribe	23
4-4	The frequency distribution of respondents according to Leishmania Past-infection (P_Infec)	24
4-5	The frequency distribution of respondents according to first leishmanin skin test (LST1)	25
4-6	The frequency distribution of respondents according to first direct agglutination test (DAT1)	26
4-7	The frequency distribution of respondents according to first Polymerases Chain Reaction (PCR1).	27
4-8	The frequency distribution of respondents according to Second leishmanin skin test (LST2)	28
4-9	The frequency distribution of respondents according to Second direct agglutination test (DAT2)	29
10-4	The frequency distribution of respondents according to Second Polymerases Chain Reaction (PCR2)	30
4-11	The frequency distribution of respondents according to Third Leishmanin Skin Test (LST3)	31
4-12	The frequency distribution of respondents according to Third Direct Agglutination Test (DAT3)	32
4-13	The frequency distribution of respondents according to Third Polymerases Chain Reaction (PCR3)	33
4-14	Correlations Among the Study Variables	34
4-15	The study variables used in the model of the logistic regression	38
4-16	The Tests of Model Coefficients	39
4-17	The most predictive indications for the disease causes in Gadarif State	40

# **List of Figures**

No.	Title	Page
4-1	The frequency distribution of respondents according to age	20
4-2	The frequency distribution of respondents according to gender.	22
4-3	The frequency distribution of respondents according to Tribe.	23
4-4	The frequency distribution of respondents according to Leishmania Past-infection (P_Infec) .	24
4-5	The frequency distribution of respondents according to leishmanin skin test (LST1).	25
4-6	The frequency distribution of respondents according to direct agglutination test (DAT1) .	26
4-7	The frequency distribution of respondents according to first Polymerases  Chain Reaction (PCR1)	27
4-8	The frequency distribution of respondents according to Second Leishmanin Skin Test (LST2).	28
4-9	The frequency distribution of respondents according to Second Direct Agglutination Test (DAT2).	29
4-10	The frequency distribution of respondents according to Second Polymerases Chain Reaction (PCR2).	30
4-11	The frequency distribution of respondents according to third Leishmanin Skin Test (LST3) .	31
4-12	The frequency distribution of respondents according to third Direct Agglutination Test (DAT3).	32
4-13	The frequency distribution of respondents according to third Polymerases Chain Reaction (PCR3).	33